Send a Tweet
Most Popular Choices
Share on Facebook 1 Share on Twitter Printer Friendly Page More Sharing
General News   

FDA Should Not Approve Painkiller Dubbed "Offspring of Vioxx"

By Press Release  Posted by Amanda Lang (about the submitter)       (Page 1 of 1 pages)     (# of views)   1 comment
Author 5
Message Amanda Lang

WASHINGTON, D.C. – Public Citizen today urged the government to reject an application for a new painkiller – Arcoxia – that is in the same class of drugs as Vioxx and, like that drug, is associated with an increased risk of cardiovascular problems.

In testimony to the Food and Drug Administration’s (FDA) Arthritis Advisory Committee, Dr. Sidney Wolfe, director of the Health Research Group at Public Citizen, said the drug should not be approved for sale in the United States, and, in fact, should be pulled from the market in the more than 60 countries where it is sold.

Arcoxia, whose generic name is etoricoxib, is a COX-2 inhibitor – a kind of painkiller once touted as a miracle cure for osteoarthritis because it was supposed to be easier on the stomach. However, data show that COX-2 inhibitors increase the risk of heart attack and other cardiovascular events. One COX-2 inhibitor, Vioxx, was pulled from the market in 2004 after studies linked it to increased risks of heart attack and stroke.

In randomized trials, etoricoxib was associated with increased cardiac risks when compared to naproxen. Further, with regards to serious gastrointestinal problems, there is no evidence of benefits of taking etoricoxib compared to diclofenac, a non-steroidal anti-inflammatory drug. Therefore, etoricoxib offers no unique benefits but carries a risk not associated with older pain relievers.

“How can the approval of etoricoxib and the large numbers of preventable, life-threatening cardiovascular adverse reactions be justified?” Wolfe asked. “Why should the similarly dangerous offspring of Vioxx be approved? The answer is that it should not.”

Wolfe pointed out that trial data presented by Merck on cardiovascular risks compared etoricoxib with diclofenac, which is much more cardio-toxic than older, safer pain relievers.

“It is time to shut the door on further additions to this dangerous class of COX-2 inhibitor drugs,” Wolfe said. “The idea that there may be certain patients, however unidentifiable they are, who might benefit from this drug is just not good enough as a basis for its approval. In addition, further trials on these COX-2 drugs are unethical and should be stopped.”

To read Wolfe’s testimony, click here.

 

Rate It | View Ratings

Amanda Lang Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

OpedNews volunteer from 2005 to 2013.

Amanda Lang was a wonderful member of the Opednews team, and the first volunteer editor, for a good number of years being a senior editor. She passed away summer 2014.

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines
Contact EditorContact Editor
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
Name
Email
   (Opens new browser window)